What Centile Bioscience does

Centile Bioscience (operating as Centile Bio) is a private, Delaware-incorporated health technology company founded in January 2023 that builds quantitative brain imaging and computational neuroscience infrastructure. Its core products are population-scale Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure for reproducible analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. Together these tools transform MRI and CT brain data into measurable quantitative insight rather than qualitative visual interpretation, using computer vision, deep learning–based brain tissue classification, predictive analytics, and harmonization of heterogeneous multi-institution datasets. The company is research-validated through publications in Nature, Radiology, JAMA Psychiatry and other high-impact journals, and through the NIH/FASEB DataWorks! Challenge Grand Prize (2023).

The company serves two defined customer segments: primary customers are research institutions and academic medical centers conducting neuroscience research and neuroimaging studies, with use cases in neurological disease research, clinical trial endpoint development and therapeutic discovery; secondary customers are pharmaceutical and biotech companies that need objective biomarkers, patient stratification and clinical trial endpoint validation for neurological therapeutics. Its go-to-market is enterprise B2B — direct research collaboration and technology licensing with leading academic and clinical partners globally — rather than a self-serve product. The company is headquartered in Wilmington, Delaware (registered address) and reports team affiliations spanning Children's Hospital of Philadelphia, University of Pennsylvania, MIT, Brigham and Women's Hospital, King's College London, University of Cambridge, Harvard MGB and AIM-Harvard, with active clinical validation programs for Alzheimer's disease and Normal Pressure Hydrocephalus.

Commercial revenue is undisclosed and the company appears to be in a pre-commercial research and validation stage: the only funding identified is the NIH/FASEB prize grant in January 2023 (which also coincided with founding), headcount is reported at 1–10, and no named commercial customers, contract values, or pricing are public. Growth is being driven by grant-funded research collaborations (TBI-REPORTER, COVID-19 long COVID consortium), diagnostic validation paper submissions, and senior hires in product, engineering, and machine learning — indicating a transition from pure research toward a licensable clinical and pharma-facing platform rather than a scaled commercial product today.

Name

Centile Bioscience

Legal name

Centile Bio

Website

https://centilebio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Centile Bioscience is a private health technology company founded in 2023 that builds AI-driven quantitative brain imaging and reference models for research institutions, academic medical centers, and pharmaceutical companies developing neurological therapeutics and clinical trial endpoints.

Ownership category

akta.pro rank

Product category

Neuroimaging Analytics Software

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Quantitative brain imaging
• Computational neuroscience
• Neuroimaging analytics
• Brain reference models
• Neurological diagnostics

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Research and Clinical Technology Licensing: The company appears to generate revenue through licensing its quantitative brain imaging technology and reference frameworks to research institutions, pharmaceutical companies, and healthcare organizations for use in clinical trials, drug discovery, and neurological disease research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Centile Bio builds advanced computational and imaging frameworks that transform complex brain data (MRI, CT) into measurable quantitative insight. Its software offerings include Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure, and an Advanced Statistical Modeling Platform for neuroimaging datasets, sold via licensing to research institutions, academic medical centers, and pharmaceutical companies for use in clinical trials, drug discovery, and neurological disease research.

Product overview

Centile Bio offers a unified quantitative neuroscience platform comprising four integrated core products: Quantitative Brain Reference Models for population-scale brain structure measurement, a Large-Scale Neuroimaging Analysis Platform for interpreting complex imaging data, Computational Modeling Infrastructure for reproducible brain analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. These products work together to transform complex brain imaging data into measurable quantitative insight, enabling earlier detection, deeper understanding, and accelerated therapeutic discovery in neurological disease.

Differentiator

Problem solved

Functional benefit

Products and services

• Quantitative Brain Reference Models Population-scale statistical frameworks for measuring brain structure and variation across individuals, ages, and populations, enabling researchers to move beyond visual interpretation toward measurable, quantitative insight for neuroscience research and clinical studies.
• Large-Scale Neuroimaging Analysis Platform Advanced statistical systems for interpreting complex brain imaging data and integrating diverse neuroimaging datasets across large cohorts, enabling consistent analysis and pattern identification for research institutions and pharmaceutical partners.
• Computational Modeling Infrastructure
• Advanced Statistical Modeling Platform for Neuroimaging Statistical modeling platform for neuroimaging datasets launched in 2024, supporting earlier detection of neurological changes and improved analytical tools for studying neurological disorders across research and clinical workflows.

Quantifiable outcome

• Earlier detection of neurological disease through quantitative biological signal identification
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• COVID-19 Consortium for Brain Charting in Long COVID PatientscoreStrategic or Co-development Partner · 1 March 2024CentileBio formed research collaboration with COVID-19 consortium to advance brain charting research specifically focused on long COVID patients, contributing to understanding of neurological impacts of the pandemic.
• Leading Research Institutions (Global)coreStrategic or Co-development PartnerGlobal scientific collaboration with leading research institutions, clinical partners, and data initiatives advancing quantitative neuroscience discovery. Millions of brain imaging data points analyzed through these partnerships.
• NIH/FASEBflagshipStrategic or Co-development PartnerCentile Bio team received DataWorks! Challenge grand prize from National Institutes of Health and Federation of American Societies for Experimental Biology, recognizing contributions to quantitative neuroscience research.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerMultiple team members are affiliated with CHOP including CEO Jakob Seidlitz and Scientific Advisor Aaron Alexander-Bloch. The company leverages CHOP's research infrastructure and neuroimaging capabilities.
• Scandx AB SwedencoreStrategic or Co-development PartnerMichael and Meera joined as co-founders through exclusive deal with Scandx AB Sweden, bringing additional expertise and technology to Centile Bio.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Brainreader: Brainreader offers AI-based brain MRI volumetrics (Neuroreader) used by clinicians and pharma trials to quantify brain changes — comparable product and customer overlap with Centile's quantitative measurement products.
• icometrix: icometrix develops AI software (icobrain) that quantitatively analyzes brain MRI/CT scans for neurological conditions including MS, dementia and TBI — the closest direct peer to Centile's quantitative brain reference and imaging-analysis platform.
• QMENTA: QMENTA provides a cloud-based neuroimaging analysis platform for clinical trials and research, very analogous to Centile's large-scale neuroimaging analysis infrastructure for multi-site brain studies.
• CorTechs Labs (NeuroQuant): CorTechs Labs commercializes NeuroQuant, an FDA-cleared brain MRI volumetric analysis tool widely used in clinical practice; directly comparable to Centile's quantitative brain measurement and diagnostic validation roadmap.
• Octave Bioscience: Octave Bioscience builds AI-enabled multi-modal diagnostics for neurodegenerative diseases (notably MS); Centile's CSPO Kelly Leyden previously led product there, and the company competes for the same neurology-diagnostics B2B customer base.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers is a major MRI and imaging AI incumbent whose AI-Rad Companion and neurology analytics compete or partner with vendors like Centile in quantitative brain measurement.
• Aidoc: Aidoc is a broad AI-imaging vendor with FDA-cleared algorithms deployed across hospital radiology workflows; competes for enterprise imaging-AI budgets that Centile would also target via its neurology-focused platform.
• GE Healthcare: GE Healthcare is a large incumbent in MRI equipment and increasingly AI-augmented neuroimaging analytics; represents the platform/channel partner versus which Centile's AI must differentiate.

Emerging players

• Neotiv: Neotiv develops digital biomarkers and AI analysis for memory and early Alzheimer's detection, overlapping with Centile's AD validation work in the same neurodegenerative diagnostic category.
• Altoida: Altoida builds AI-based digital cognitive and brain-health assessment tools targeting early detection of neurodegenerative disease, addressing similar end-markets via a different (digital-cognitive) modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/centile-bioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centile Bioscience